These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 33686576)

  • 1. Molecular recognition of tak-285 and lapatinib by inactive, active, and middle active-inactive HER2.
    Martiniano B
    J Mol Model; 2021 Mar; 27(4):105. PubMed ID: 33686576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural and energetic basis for the molecular recognition of dual synthetic vs. natural inhibitors of EGFR/HER2.
    Bello M; Saldaña-Rivero L; Correa-Basurto J; García B; Sánchez-Espinosa VA
    Int J Biol Macromol; 2018 May; 111():569-586. PubMed ID: 29329808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissecting the molecular recognition of dual lapatinib derivatives for EGFR/HER2.
    Bello M; Guadarrama-García C; Rodriguez-Fonseca RA
    J Comput Aided Mol Des; 2020 Mar; 34(3):293-303. PubMed ID: 31828486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atomistic insights into the lung cancer-associated L755P mutation in HER2 resistance to lapatinib: a molecular dynamics study.
    Yang B; Zhang H; Wang H
    J Mol Model; 2015 Feb; 21(2):24. PubMed ID: 25620423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold.
    Ishikawa T; Seto M; Banno H; Kawakita Y; Oorui M; Taniguchi T; Ohta Y; Tamura T; Nakayama A; Miki H; Kamiguchi H; Tanaka T; Habuka N; Sogabe S; Yano J; Aertgeerts K; Kamiyama K
    J Med Chem; 2011 Dec; 54(23):8030-50. PubMed ID: 22003817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative anti-proliferative effects of potential HER2 inhibitors on a panel of breast cancer cell lines.
    Zalloum H; AbuThiab T; Hameduh T; AlBayyari S; Zalloum W; Abu-Irmaileh B; Mubarak MS; Zihlif M
    Breast Cancer; 2020 Mar; 27(2):213-224. PubMed ID: 31559601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer.
    Meng X; Li Y; Tang H; Mao W; Yang H; Wang X; Ding X; Xie S
    Amino Acids; 2016 Feb; 48(2):487-97. PubMed ID: 26439378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model.
    Nakayama A; Takagi S; Yusa T; Yaguchi M; Hayashi A; Tamura T; Kawakita Y; Ishikawa T; Ohta Y
    J Cancer; 2013; 4(7):557-65. PubMed ID: 23983820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
    Gilmer TM; Cable L; Alligood K; Rusnak D; Spehar G; Gallagher KT; Woldu E; Carter HL; Truesdale AT; Shewchuk L; Wood ER
    Cancer Res; 2008 Jan; 68(2):571-9. PubMed ID: 18199554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients.
    Doi T; Takiuchi H; Ohtsu A; Fuse N; Goto M; Yoshida M; Dote N; Kuze Y; Jinno F; Fujimoto M; Takubo T; Nakayama N; Tsutsumi R
    Br J Cancer; 2012 Feb; 106(4):666-72. PubMed ID: 22240796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico design: extended molecular dynamic simulations of a new series of dually acting inhibitors against EGFR and HER2.
    Ahmed M; Sadek MM; Abouzid KA; Wang F
    J Mol Graph Model; 2013 Jul; 44():220-31. PubMed ID: 23911931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitor Response to HER2 G776(YVMA) In-frame Insertion in HER2-positive Breast Cancer.
    Zheng YB; Yu Y; Chen B; Hu JL; Jing T; Zhang XP
    Cancer Invest; 2016; 34(3):123-9. PubMed ID: 26934461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein.
    Aertgeerts K; Skene R; Yano J; Sang BC; Zou H; Snell G; Jennings A; Iwamoto K; Habuka N; Hirokawa A; Ishikawa T; Tanaka T; Miki H; Ohta Y; Sogabe S
    J Biol Chem; 2011 May; 286(21):18756-65. PubMed ID: 21454582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of substituted 6-salicyl-4-anilinoquinazoline derivatives as dual EGFR/HER2 tyrosine kinase inhibitors.
    Li DD; Qin YJ; Sun J; Li JR; Fang F; Du QR; Qian Y; Gong HB; Zhu HL
    PLoS One; 2013; 8(8):e69427. PubMed ID: 23936329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2.
    Kim HP; Yoon YK; Kim JW; Han SW; Hur HS; Park J; Lee JH; Oh DY; Im SA; Bang YJ; Kim TY
    PLoS One; 2009 Jun; 4(6):e5933. PubMed ID: 19529774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Verification of brain penetration of the unbound fraction of a novel HER2/EGFR dual kinase inhibitor (TAK-285) by microdialysis in rats.
    Erdo F; Gordon J; Wu JT; Sziráki I
    Brain Res Bull; 2012 Mar; 87(4-5):413-9. PubMed ID: 22245027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of tyrosine kinase inhibitors from Panax bipinnatifidus and Panax pseudoginseng for RTK-HER2 and VEGFR2 receptors, by in silico approach.
    Paul D; Mahanta S; Tag H; Das SK; Das Gupta D; Tanti B; Ananthan R; Das R; Jambhulkar S; Hui PK
    Mol Divers; 2022 Aug; 26(4):1933-1955. PubMed ID: 34554395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repurposing FDA Drug Compounds against Breast Cancer by Targeting EGFR/HER2.
    Balbuena-Rebolledo I; Padilla-Martínez II; Rosales-Hernández MC; Bello M
    Pharmaceuticals (Basel); 2021 Aug; 14(8):. PubMed ID: 34451888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic analysis of the resistance and sensitivity of HER2YVMA receptor tyrosine kinase mutant to tyrosine kinase inhibitors in HER2-positive lung cancer.
    Shen X; Chen B; Ma Z; Xie B; Cao X; Yang T; Zhao Y; Qin J; Li J; Cao F; Chen X
    J Recept Signal Transduct Res; 2016; 36(1):89-97. PubMed ID: 26391018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.